Survey of Serum Procalcitonin in Cirrhotic Patients

  • Monireh Rahimkhani Department of Lab Medical Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
  • Nahid Einollahi Department of Lab Medical Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
  • Hossein Khavari Daneshvar Mail Cancer Research Center, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran.
  • Nasrin Dashti Department of Lab Medical Sciences, Faculty of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran.
Keywords:
Cirrhosis, Infection, Procalcitonin

Abstract

Procalcitonin (PCT) is a prohormone that has been used as a marker for the diagnosis of bacterial infections. The aim of this study was to survey PCT levels in patients with cirrhosis. Sixty-four patients with hepatic cirrhosis and 32 healthy blood donors were enrolled in this study. Serum PCT levels was detected using immunoluminometric assay. The rate of positive PCT was higher in patients with hepatitis C cirrhosis (92.8%) than the other groups. Among other cirrhotic patients, positive PCT levels were 77% for hepatitis B, 70% for cancer and 53.3% for unknown groups respectively. Serum procalcitonin levels were significantly higher in cirrhotic patients with bacterial infection (2.65±1.11 ng/ml) than those without infection (0.59±0.16 ng/ml, P=0.0001). PCT assay in cirrhotic patients may help diagnosis of sepsis and reduce unnecessary antibiotic use.

References

Hatzistilianou M. Diagnostic and prognostic role of procalcitonin in infections.Scientific World Journal 2010; 10:1941-6.

Morgenthaler NG, Struck J, Chancerelle Y, Weglohner W, Agay D, Bohuon, C .Production of procalcitonin (PCT) in non thyroidal tissue after LPS injection.Horm Metab Res2003;35: 290–295.

Balog A, Ocsovszki I, Mandi Y. Flowcytometric analysis of Procalcitonin expression in human monocytes and granulocytes. Immunol Lett 2002;84:199–203.

Russwurm S, Stonans I, Stonane E, Wiederhold M, LuberA, Zipfel PF, et al. Procalcitonin and CGRP-1 mRNA expression in Various human tissues. Shock 2001;16:109–12.

Husova L, Husa P, Senkyrik M, Lata J. Procalcitonin as an indicator of infection in patients with liver cirrhosis. Vnitr Lek 2004 Feb;50(2):153-6.

Oshita H, Sakurai J, Kamitsuna M. Semi-quantitative procalcitonin test for the diagnosis of bacterial infection:clinical use and experience in Japan. J Microbial Immunol Infect 2010;43(3):222-7.

Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546–54.

Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G,Carcillo J,Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303–10.

World Health Organization (WHO). WHO report on infectious disease: removingobstacles to healthy development. Geneva: WHO,1999.www.who.int/infectious-disease-report/index

Rahimkhani M, Ghofrani H. Helicobacterpylori and peptic ulcer in cirrhotic patients. Pak J Med Scien 2008;24(6):84952.

Kim MH , Lim G, Kang SY , Lee WI, Suh JT, Lee HJ. Utility of procalcitonin as an early diagnostic marker of bacteremia in patients with acute fever. Yonsei med J 2011;5(2):276-81.

Rahimkhani M, Khavari Daneshvar H, Jamali S. Serologic evaluation of hepatitis B and D in patients with cirrhosis. African J Microb Research 2011; 5(5):568-571.

Michalik DE, Duncan BW, Mee RBB, Worley S,GoldfarbJ, Danziger-Isakov LA, Davis SJ, Harrison AM, Appachi E, Sabella C. Quantitative analysis of procalcitonin after pediatriccardiothoracic surgery. Cardiol Young 2006;16:48–53.

Bienvenu J, Monneret G. Procalcitonin as an acute phase marker. Ann Clin Biochem 2001; 38:483–93.

Nijsten MW, Olinga P, The TH. Procalcitonin behaves as a fastresponding acute phase protein in vivo and in vitro. Crit Care Med 2000; 28:458–61.

Oberhoffer M, Stonans I, Russwurm S. Procalcitoninexpressionin human peripheral blood mononuclear cellsand its modulation bylipopolysaccharides and sepsisrelated cytokines in vitro. J Lab Clin Med 1999; 134:49–55.

Simon L, Gauvin F, Amre DK, Saint-Louis p, Lacroix J,Whicher J. Serum Procalcitonin and C-Reactive Protein Levels as Markers of Bacterial Infection: A Systematic Review and Meta-analysis. Clinical Infectious Diseases 2004; 39:206–17.

Elefsiniotis IS, Petrocheilou A, Scarmeas N, Ketikoglou I, Pantazis KD, Toutouza M, Tsianos EV. Serum procalcitonin levels in chronic hepatitis C patients under pegylated interferon-alpha plus ribavirin treatment. Journal of Clinical Virology 2006;37:329–31

Oruc N, Ozutemiz O, Yuce G, Akarca US, Ersoz G,Gunsar F, Batur Y. Serum procalcitonin and CRP levels innon-alcoholic fatty liver disease: a case control study.BMC Gastroenterology 2009;9:16.

Viallon A , Guyomarc'h P, Guyomarc'h S, Tardy B, Robert F, Marjollet O. Decrease in serum procalcitonin levels over time during treatment of acute bacterial meningitis. Crit Care 2005;9(4):R344–R350.

Stojanović-Spehar S, Blazeković-Milaković S, Bergman- Marković B, Vrca-Botica M.Prescribing antibiotics to preschool children in primary health care in Croatia. CollAntropol 2008;32(1):125-30.

How to Cite
1.
Rahimkhani M, Einollahi N, Khavari Daneshvar H, Dashti N. Survey of Serum Procalcitonin in Cirrhotic Patients. Acta Med Iran. 51(3):153-156.
QRcode
Section
Articles